

IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

1. (original) A method of treatment of a disease in which IL13 and IL4 cause adverse effects, which method comprises administration to a patient of a polypeptide comprising SEQ ID NO:9.
2. (original) A method of treatment of a disease in which IL13 and IL4 cause adverse effects, which method comprises administration to a patient of a soluble polypeptide comprising SEQ ID NO:9.
3. (original) A method of treatment according to claim 1 in which the disease is characterised by IgE or Th2 differentiation.
4. (original) A method of treatment according to claim 1 in which the disease is selected from the group consisting of atopy, atopic dermatitis, an allergy, rhinitis, eczema, asthma, and AIDS.
5. (original) A method of treatment according to claim 1 in which the disease is a respiratory disorder.
6. (original) A method of treatment according to claim 1 in which the disease is asthma.
7. (original) A method of treatment of a disease in which IL13 and IL4 cause adverse effects, which method comprises administration to a patient of a soluble polypeptide which is capable of binding human IL13 and/or human IL4 in the presence of IL4R α or which is bound to human IL13 and/or human IL4 which comprises the amino acid sequence shown in SEQ ID NO:9.

8. (original) A method of treatment of a disease in which IL13 and IL4 cause adverse effects, which method comprises administration to a patient of a soluble polypeptide which comprises the amino acid sequence shown in SEQ ID NO:9 wherein the Thr residue number 130 and the Gly residue number 358 shown in SEQ ID NO:9 are replaced by Ile and Asp residues, respectively.

9. (original) A method of treatment according to claim 7 or 8 in which the disease is characterised by IgE or Th2 differentiation.

10. (original) A method of treatment according to claim 7 or 8 in which the disease is selected from the group consisting of atopy, atopic dermatitis, an allergy, rhinitis, eczema, asthma, and AIDS.

11. (original) A method of treatment according to claim 7 or 8 in which the disease is a respiratory disorder.

12. (original) A method of treatment according to claim 7 or 8 in which the disease is asthma.

13. (original) A composition comprising a soluble polypeptide comprising SEQ ID NO:9 in admixture with a carrier.

14. (original) A composition comprising a soluble polypeptide comprising SEQ ID NO:9 wherein the Thr residue number 130 and the Gly residue number 358 shown in SEQ ID NO:9 are replaced by Ile and Asp residues, respectively, in admixture with a carrier.

15. (original) A method of treatment of a disease characterised by IgE or Th2 differentiation, which method comprises administration to a patient of a composition according to claim 13 or 14.

16. (original) A method of treatment of a disease selected from the group consisting of atopy, atopic dermatitis, an allergy, rhinitis, eczema, asthma, and AIDS; which method comprises administration to a patient of a composition according to claim 13 or 14.

17. (original) A method of treatment of a disease which is a respiratory disorder, which method comprises administration to a patient of a composition according to claim 13 or 14.

18. (original) A method of treatment of a disease which is asthma, which method comprises administration to a patient of a composition according to claim 13 or 14.

19. (original) A method of decreasing IL13 and/or IL4 levels in a patient's body, which method comprises administration to a patient of a soluble polypeptide comprising SEQ ID NO:9.

20. (original) A method of decreasing IL13 and/or IL4 levels in a patient's body, which method comprises administration to a patient of a soluble polypeptide comprising SEQ ID NO:9 wherein the Thr residue number 130 and the Gly residue number 358 shown in SEQ ID NO:9 are replaced by Ile and Asp residues, respectively.

21. (original) The use of a polypeptide comprising SEQ ID NO:9 or a polypeptide comprising SEQ ID NO:9 wherein the Thr residue number 130 and the Gly residue number 358 shown in SEQ ID NO:9 are replaced by Ile and Asp residues, respectively, in raising or selecting antibodies.

22. (original) An antibody, an antibody fragment, or a synthetic construct thereof which is capable of binding to a polypeptide comprising SEQ ID NO:9 or a polypeptide comprising SEQ ID NO:9 wherein the Thr residue number 130 and the Gly residue number 358 shown in SEQ ID NO:9 are replaced by Ile and Asp residues, respectively.